Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 16, 2026Tissue Barriers

Erlotinib impairs epidermal tight junction and barrier integrity by inhibiting EGFR and Src and affects maturation of cell–cell junctions in human and mouse keratinocytes

View Full Paper
Ask AI
Bookmark
Share

Authors

KIKeisuke ImafukuAGAlexander García‐PonceJWJens Waschke

Discussion

Loading...

Member takes

Overview

Randomized trial examines erlotinib's effect on epidermal barrier in keratinocytes, suggesting new treatment strategies.

Key Points

  • The aim is to investigate how erlotinib, an EGFR inhibitor, affects epidermal barrier integrity and tight junction stability.
  • Examined human and mouse ex vivo epidermis alongside cultured keratinocytes.
  • Assessed junctional stability and assembly under pharmacological inhibition of EGFR and Src.
  • Utilized biotin tracer penetration and transepithelial electrical resistance measurements.
  • Erlotinib treatment caused enhanced biotin tracer penetration and reduced transepithelial electrical resistance.
  • The treatment disrupted claudin-1 and ZO-1 localization, resulting in impaired junction maturation.
  • EGF treatment could rescue barrier integrity, suggesting tension-related mechanisms can mitigate cutaneous toxicities.

Cite This Study

Imafuku et al. (2026) studied this question.

synapsesocial.com/papers/6a5874652b46c88ba9ad07d4https://doi.org/10.1080/21688370.2026.2696758
View Full Paper
Ask AI
Bookmark
Share